Project Grant R56ES037610
- This federal Project Grant award, provided by the Department of Health and Human Services National Institutes of Health under the Trans-NIH Research Support program (CFDA 93.310), funds research to investigate mast cell activation as a common mechanism of pulmonary toxicity caused by chemical threat agents. The $1,395,741 award to the University of Colorado-Denver, effective September 1, 2025 through August 31, 2028, will support two specific aims. The research aims to confirm the in vivo...
- The U.S. Department of Health and Human Services National Institutes of Health (NIH) awarded a $226,464 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to the University of Wisconsin-Milwaukee on June 11, 2025. The grant funding will support research to demonstrate the therapeutic efficacy of gamma aminobutyric acid type A receptor (GABAAR) modulators in reducing acute lung injury caused by inhaled chlorine exposure. The research aims to develop medical countermeasures...
- This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $235,500 to Rutgers, The State University of New Jersey to conduct research on reducing chlorine-induced lung toxicity through the inhibition of macrophage activation. The research aims to develop medical countermeasures to mitigate the severe respiratory complications that can result from exposure to chlorine, a reactive gas that has been used as a chemical warfare...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $462,501 to The Regents of the University of Colorado, doing business as University of Colorado-Denver, to conduct research on mast cell activation as a common mechanism of pulmonary toxicity from chemical threat agents. The two-year project aims to examine how activation of mast cells contributes to lung inflammation and injury caused by exposure to various...
- This federal Project Grant award, funded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), supports research on the role of acetylcholine and the endocannabinoid system in cognition and reward processing. The $760,143 award was granted to the University of Maryland, Baltimore to conduct studies using animal models and human subjects to investigate the interaction between cholinergic neurotransmission and cannabinoid receptors in...
- The Project Grant award of $675,107 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research to develop novel non-opioid, non-addictive analgesics for treating neuropathic pain. The project, led by Northeastern University, will focus on designing and evaluating "dualsteric modulators" that act as both cannabinoid CB1 receptor...
- This Project Grant award of $144,950.00 from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) aims to evaluate the expression, function, and immunomodulatory potential of endocannabinoid receptors, including TRPV2 and PPAR-A, as well as cannabidiol (CBD), in microglia in the context of HIV. The research goal is to investigate how the endocannabinoid system can modulate the HIV-induced inflammatory response in microglia, which is a key driver of...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $465,750 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Virginia Commonwealth University (VCU). The award will fund research to develop novel mu opioid receptor (MOR) modulators to counteract the effects of synthetic opioids, which are fueling the opioid crisis in the United States. Specifically, the project will design, synthesize, and characterize a...
- This federal Project Grant award of $385,638 was provided by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, under the Drug Use and Addiction Research Programs (CFDA 93.279). The purpose of the grant is to conduct research on the neurobehavioral consequences of chronic exposure to synthetic cannabinoids, also known as "synthetic marijuana", across different stages of lifespan development and between sexes. The research aims to elucidate the...
- This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will provide $350,000 to Creighton University to investigate the effects of environmental enrichment on the abuse liability of minor cannabinoids such as delta-8-THC and CBD. The research aims to determine if adolescent exposure to high- or low-novelty environments can alter sensitivity to these cannabis compounds using animal models....
This federal Project Grant award from the U.S. Department of Health and Human Services (HHS) National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $489,008 to Old Dominion University to investigate how enhancing the endocannabinoid signaling system, specifically by inhibiting the enzyme monoacylglycerol lipase (MAGL), could confer protection against lung injury caused by chemical threat agents such as nitrogen mustard and ammonia. The research aims to build on the university's preliminary findings indicating that acute exposure to these chemical agents results in a significant increase in MAGL in mouse lung tissue and human alveolar macrophages. The award will fund a 1-year project period from September 15, 2025 to September 14, 2026 to further explore this therapeutic approach.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $489.0k | 9/15/25 |